U.S. Markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
224.10+1.50 (+0.67%)
At close: 05:29PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close222.60
Bid223.00 x 0
Ask223.30 x 0
Day's Range221.60 - 225.80
52 Week Range156.00 - 245.40
Avg. Volume772,083
Market Cap66.142B
Beta (5Y Monthly)0.45
PE Ratio (TTM)22.67
EPS (TTM)9.89
Earnings DateMay 02, 2022 - May 06, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est250.50
  • GlobeNewswire

    Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH)

    INTO-HLH Registry serves as the first in-depth disease registry for the HLH medical and patient community in North AmericaWALTHAM, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Sobi® North America today announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis (HLH). The INTO-HLH Registry (Insight into the Natural history and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis) will enroll pediatric and adult patients with HLH, a r

  • Zacks

    Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?

    Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • PR Newswire

    Sobi to present new data at ISTH 2022

    Sobi® will present new data at ISTH 2022, the 30th Congress of the International Society on Thrombosis and Haemostasis, taking place online and in London from 9 to 13 July. ISTH gathers the world's leading experts to present recent advances, exchange science and discuss clinical applications designed to improve patient care within haematology. Six abstracts featuring three medicines have been accepted for presentation, reflecting the relevance of the new data which confirms Sobi's commitment to